卡瑞利珠单抗联合放化疗对晚期食管癌疗效及安全性的Meta分析  

The curative and security of Camrelizumab for injection combined with radiotherapy or chemotherapy in advanced esophageal cancer:a Meta-analysis

作　　者：刘丽 左晓林 赵志鹏 杨淯钧 宋应明[2] LIU Li;ZUO Xiaolin;ZHAO Zhipeng;YANG Yujun;SONG Yingming(The First Clinical College,Changzhi Medical College,Channgzhi 046000;Department of Surgical Oncology,Heping Hospital Affiliated to Changzhi Medical College,China)

机构地区：[1]长治医学院第一临床学院,山西长治046000 [2]长治医学院附属和平医院肿瘤外科

出　　处：《胃肠病学和肝病学杂志》2025年第2期258-264,共7页Chinese Journal of Gastroenterology and Hepatology

基　　金：2021年山西省高等学校大学生创新创业训练计划项目(20210580,J2021522)。

摘　　要：目的系统探讨卡瑞利珠联合放化疗在治疗晚期食管癌中的疗效及安全性。方法计算机检索PubMed、CNKI、万方、维普等数据库,查询卡瑞利珠单抗免疫治疗食管癌的相关研究,采用RevMan 5.3软件进行Meta分析。纳入的研究为双臂随机对照试验(randomized controlled trial,RCT)及少量的回顾性分析。结果共纳入10项研究,包含了1231例晚期食管癌患者。Meta分析结果显示,使用卡瑞利珠单抗联合放化疗能够有效提高食管癌患者的客观缓解率(partial remission,PR)、病灶稳定率(stabilization of disease,SD),能够一定程度上降低食管癌患者的病灶进展率(progression disease,PD),且具有可管理的安全性。结论卡瑞利珠单抗结合放化疗可以提高食管癌患者的疗效,且显示出优于传统放化疗的安全性。Objective To systematically explore the curative effect and safety of Camrelizumab combined with radiotherapy or chemotherapy in advanced esophageal cancer.Methods Literatures from PubMed,CNKI,WanFang,VIP were searched to query the related studies of immunotherapy for esophageal cancer.RevMan 5.3 was used for Metaanalysis.The inclusion criteria for the studies were double-blind randomized controlled trial(RCT)and a few retrospective study.Results There were 10 RCTs and 1231 patients with esophagel cancer.It showed that Camrelizumab for injection combined with radiotherapy or chemotherapy can obviouely improve the PR,SD of the study group and reduce the PD of the study group effectively,which showed better safety than traditional radiotherapy and chemotherapy.Conclusion The combination of Carilizumab and radiotherapy chemotherapy can improve the efficacy of esophageal cancer patients and demonstrate superior safety compared to traditional radiotherapy chemotherapy.

关 键 词：食管癌 卡瑞利珠单抗 放化疗 

分 类 号：R735.1[医药卫生—肿瘤]